Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $796.82
Incyte Corp and Novartis AG on Monday said a phase 3 study of ruxolitinib in Covid-19 patients failed to meet its pri ...
The following is a round-up of updates by global companies, issued on Thursday and Friday and not separately reported ...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.